ARTICLE | Company News
Boehringer Ingelheim, Medivir deal
August 11, 2014 7:00 AM UTC
Boehringer Ingelheim granted Medivir exclusive, worldwide rights to develop and commercialize compounds that inhibit the RSV fusion protein to treat and prevent respiratory syncytial virus (RSV) infec...